DIAMYD: A hot cup of Java! :)A cup and a handle if I ever saw one!
Diamyd has been reporting some great news lately: the Diamyd vaccine showing great results in clinical trials conducted in January this year , as well as getting their manufacturing plant ready for production of the vaccine!
Notice the rising trend in a
−0.11EUR
−9.73 MEUR
45.78 KEUR
81.95 M
About DIAMYD MEDICAL AB SER. B
Sector
CEO
Ulf Hannelius
Headquarters
Stockholm
Website
Employees (FY)
25
Founded
1984
ISIN
SE0005162880
Diamyd Medical AB engages in the development of pharmaceutical products for the treatment of diabetes and other serious inflammatory diseases. Its pipeline includes Diamyd and Remygen which targets the underlying causes of diabetes, dysfunction, and loss of the pancreatic beta cells. It also develops and invests in stem cell and medical technology. The company was founded by Anders Essen-Moller in 1996 and is headquartered in Stockholm, Sweden.
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of DMN is 1.00 EUR — it hasn't changed in the past 24 hours. Watch DIAMYD MEDICAL AB stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange DIAMYD MEDICAL AB stocks are traded under the ticker DMN.
DMN stock has fallen by 9.58% compared to the previous week, the month change is a 21.36% rise, over the last year DIAMYD MEDICAL AB has showed a 22.12% decrease.
DMN stock is 0% volatile and has beta coefficient of 0.91. Track DIAMYD MEDICAL AB stock price on the chart and check out the list of the most volatile stocks — is DIAMYD MEDICAL AB there?
Today DIAMYD MEDICAL AB has the market capitalization of 101.58 M, it has increased by 1.53% over the last week.
Yes, you can track DIAMYD MEDICAL AB financials in yearly and quarterly reports right on TradingView.
DMN net income for the last quarter is −2.60 M EUR, while the quarter before that showed −2.86 M EUR of net income which accounts for 9.06% change. Track more DIAMYD MEDICAL AB financial stats to get the full picture.
No, DMN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 23, 2024, the company has 25.00 employees. See our rating of the largest employees — is DIAMYD MEDICAL AB on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. DIAMYD MEDICAL AB EBITDA is −10.32 M EUR, and current EBITDA margin is −20.64 K%. See more stats in DIAMYD MEDICAL AB financial statements.
Like other stocks, DMN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade DIAMYD MEDICAL AB stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So DIAMYD MEDICAL AB technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating DIAMYD MEDICAL AB stock shows the sell signal. See more of DIAMYD MEDICAL AB technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.